Plenvu powder for oral solution
Authorisation PA1336/005/001 · Norgine B.V.
- Licence holder
- Norgine B.V. (all products →)
- Active substances
- Macrogol 3350, Sodium sulfate anhydrous, Sodium chloride, Potassium chloride, Macrogol 3350, Sodium chloride, Potassium chloride, Sodium ascorbate, Ascorbic acid
- Clinical trials
- 3 clinical trials → 3 clinical trials → 2 clinical trials →
- Dosage form
- Powder for oral solution
- Route of administration
- Oral use
- ATC codes
- A06AD, A06AD65
- First authorised
- 01/12/2017
- Prescription status
- Product subject to prescription which may be renewed (B)
- Supply
- Supply through pharmacies only
- Legal basis
- Fixed combination application (Article 10b of Directive No 2001/83/EC)
Macrogol 3350: supply and approvals
19 authorised products on the HPRA list contain Macrogol 3350. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.
- EU shortage (EMA)
- No entry in the EMA shortage catalogue (checked 18 Nov 2026)
- US shortage (FDA)
- No entry in the FDA drug shortage list (checked 18 Nov 2026)
- Germany (BfArM)
- No entry in the BfArM supply notices (checked 18 Nov 2026)
Registers: EU shortages · US shortages · German shortages · EMA approvals
Sodium sulfate anhydrous: supply and approvals
126 authorised products on the HPRA list contain Sodium sulfate anhydrous. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.
- EU shortage (EMA)
- No entry in the EMA shortage catalogue (checked 18 Nov 2026)
- US shortage (FDA)
- Sodium Acetate Injection: in shortage, updated 15 Nov 2026
- Germany (BfArM)
- No entry in the BfArM supply notices (checked 18 Nov 2026)
Registers: EU shortages · US shortages · German shortages · EMA approvals
Sodium chloride: supply and approvals
126 authorised products on the HPRA list contain Sodium chloride. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.
- EU shortage (EMA)
- No entry in the EMA shortage catalogue (checked 18 Nov 2026)
- US shortage (FDA)
- Sodium Acetate Injection: in shortage, updated 15 Nov 2026
- Germany (BfArM)
- No entry in the BfArM supply notices (checked 18 Nov 2026)
Registers: EU shortages · US shortages · German shortages · EMA approvals
About this licence
National authorisation (PA). A product authorisation granted by the HPRA for the Irish market. It has been authorised for 8 years (since 1 December 2017). The HPRA list marks it as marketed in Ireland.
Other medicines with Macrogol 3350 in Ireland
18 other products on the HPRA list contain Macrogol 3350, from 9 licence holders; 7 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.
| Medicine | Licence holder | Licence | Status |
|---|---|---|---|
| Laxido Orange, powder for oral solution | Galen Pharma Ireland Limited | National authorisation (PA) | Marketed |
| Laxido Paediatric Plain, 6.9 g sachet, powder for oral solution | Galen Pharma Ireland Limited | National authorisation (PA) | Marketed |
| Macrolief 13.8g sachet, powder for oral solution | Rowex Limited, | National authorisation (PA) | Marketed |
| Molaxole powder for oral solution | Viatris Healthcare Limited | National authorisation (PA) | Marketed |
| Movicol 13.8 g sachet powder for oral solution | Norgine Healthcare B.V. | National authorisation (PA) | Marketed |
| Movicol Paediatric Plain 6.9 g sachet powder for oral solution | Norgine Healthcare B.V. | National authorisation (PA) | Marketed |
| Moviprep, powder for oral solution | Norgine B.V. | National authorisation (PA) | Marketed |
| Laxido, powder for oral solution | Galen Pharma Ireland Limited | National authorisation (PA) | Not marketed |
| MOVIPREP, powder for oral solution | PCO Manufacturing Ltd. | Parallel import (PPA) | Not stated |
| Movicol Paediatric Chocolate Flavour 6.9 g sachet powder for oral solution | Norgine Healthcare B.V. | National authorisation (PA) | Not marketed |
| Movicol 13.8g sachet, powder for oral solution | Novalus Healthcare Limited | Parallel import (PPA) | Not stated |
| Movicol Chocolate 13.9 g sachet powder for oral solution | Norgine Healthcare B.V. | National authorisation (PA) | Not marketed |
Other medicines with Sodium sulfate anhydrous in Ireland
3 other products on the HPRA list contain Sodium sulfate anhydrous, from 2 licence holders; 1 of them is marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.
| Medicine | Licence holder | Licence | Status |
|---|---|---|---|
| Moviprep, powder for oral solution | Norgine B.V. | National authorisation (PA) | Marketed |
| Moviprep Orange, powder for oral solution | Norgine B.V. | National authorisation (PA) | Not marketed |
| Moviprep, powder for oral solution | IMED Healthcare Ltd., | Parallel import (PPA) | Not stated |
Other substances in ATC group A06AD
The ATC system groups medicines by the part of the body they act on and their chemistry. On the HPRA list, 9 other active substances share the group A06AD with this product:
Sodium hydrogen carbonate (9) · Lactulose (6) · Sodium bicarbonate (4) · Macrogol 4000 (2) · Magnesium sulphate dihydrate (1) · Citric acid (1) · Sodium sulphate anhydrous (1) · Sodium phosphate dibasic dihydrate (1) · Disodium phosphas dodecahydrate (1)
Numbers in brackets are products on the HPRA list. Sharing an ATC group does not mean two medicines can replace each other.
The licence holder
Norgine B.V. holds 11 products on the HPRA list, with 13 different active substances; 4 of the products are marked as marketed.
This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.
How this page is built
The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.
- HPRA Authorised Medicines List (open data) ↗ Licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status for this product
This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 19 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.